Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Summary
Third Opinion Trial Synopsis:
This study will compare two different ways to treat a type of cancer called multiple myeloma. The study will randomly assign patients to receive either one treatment plan (KRD) or another (VRD). The goal is to figure out which treatment works better for people who are just diagnosed with this type of cancer.
This study will compare two different ways to treat a type of cancer called multiple myeloma. The study will randomly assign patients to receive either one treatment plan (KRD) or another (VRD). The goal is to figure out which treatment works better for people who are just diagnosed with this type of cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: